Since the biggest challenge in targeting cancer is directly correlated with the ligands’ ability to specifically recognize the cancer cells, bombesin (BN) receptors have shown to increase on-site delivery mechanisms and present a promising approach for tumor targeting [44,45]. This evidence concerns the gene GRP and neoplasm.